{
    "root": "dcc1e99e-f977-4f78-8d54-1049e0d7d28b",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Triazolam",
    "value": "20250528",
    "ingredients": [
        {
            "name": "TRIAZOLAM",
            "code": "1HM943223R"
        },
        {
            "name": "POWDERED CELLULOSE",
            "code": "SMD1X3XO9M"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "DOCUSATE SODIUM",
            "code": "F05Q2T2JA0"
        },
        {
            "name": "LACTOSE, UNSPECIFIED FORM",
            "code": "J2B2A4N98G"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "SODIUM BENZOATE",
            "code": "OJ245FE5EU"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        }
    ],
    "indications": "triazolam indicated short-term treatment insomnia ( generally 7 10 days ) adults .",
    "contraindications": "• adults : recommended 0.25 mg daily bedtime . maximum recommended 0.5 mg daily ( 2.1 ) • geriatric patients : reduce starting 0.125 mg daily . may increase 0.25 mg response . geriatric patients exceed 0.25 mg daily ( 2.2 , 8.5 ) • triazolam prescribed quantities exceeding 1-month supply ( 2.1 )",
    "warningsAndPrecautions": "triazolam supplied 0.125 mg white tablet 0.25 mg powder blue , scored tablet following strengths package configurations : package configuration tablet strength ( mg ) ndc print bottles 10 0.125 mg ndc 59762-3717-4 g3717 bottles 100 0.125 mg ndc 59762-3717-9 g3717 bottles 10 0.25 mg ndc 59762-3718-4 g3718 bottles 100 0.25 mg ndc 59762-3718-9 g3718 bottles 500 0.25 mg ndc 59762-3718-3 g3718",
    "adverseReactions": "triazolam contraindicated : •patients known hypersensitivity triazolam , component triazolam , benzodiazepines . consistent angioedema ( involving tongue , glottis , larynx ) , dyspnea , throat closing reported may fatal . •concomitant strong cytochrome p450 ( cyp 3a ) enzyme inhibitors ( e.g . , ketoconazole , itraconazole , nefazodone , lopinavir , ritonavir ) [ ( 5.8 ) , ( 7.1 ) ] .",
    "indications_original": "Triazolam is indicated for the short-term treatment of insomnia (generally 7 to 10 days) in adults.",
    "contraindications_original": "• Adults : Recommended dosage is 0.25 mg once daily before bedtime. Maximum recommended dosage is 0.5 mg once daily ( 2.1 ) • Geriatric patients : Reduce starting dosage to 0.125 mg once daily. May increase to 0.25 mg if no response. Geriatric patients should not exceed 0.25 mg once daily ( 2.2 , 8.5 ) • Triazolam should not be prescribed in quantities exceeding a 1-month supply ( 2.1 )",
    "warningsAndPrecautions_original": "Triazolam is supplied as a 0.125 mg white tablet or a 0.25 mg powder blue, scored tablet in the following strengths and package configurations:\n                  \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              Package Configuration\n                           \n                           \n                              Tablet Strength (mg)\n                           \n                           \n                              NDC\n                           \n                           \n                              Print\n                           \n                        \n                     \n                     \n                        \n                           \n                              Bottles of 10\n                           \n                           \n                              0.125 mg\n                           \n                           \n                              NDC 59762-3717-4\n                           \n                           \n                              G3717\n                           \n                        \n                        \n                           \n                              Bottles of 100\n                           \n                           \n                              0.125 mg\n                           \n                           \n                              NDC 59762-3717-9\n                           \n                           \n                              G3717\n                           \n                        \n                        \n                           \n                              Bottles of 10\n                           \n                           \n                              0.25 mg\n                           \n                           \n                              NDC 59762-3718-4\n                           \n                           \n                              G3718\n                           \n                        \n                        \n                           \n                              Bottles of 100\n                           \n                           \n                              0.25 mg\n                           \n                           \n                              NDC 59762-3718-9\n                           \n                           \n                              G3718\n                           \n                        \n                        \n                           \n                              Bottles of 500\n                           \n                           \n                              0.25 mg\n                           \n                           \n                              NDC 59762-3718-3\n                           \n                           \n                              G3718",
    "adverseReactions_original": "Triazolam is contraindicated in:\n                  \n                     \n                        •Patients with known hypersensitivity to triazolam, any of component of triazolam, or other benzodiazepines. Reactions consistent with angioedema (involving the tongue, glottis, or larynx), dyspnea, and throat closing have been reported and may be fatal. \n                     \n                        •Concomitant administration of strong cytochrome P450 (CYP 3A) enzyme inhibitors (e.g., ketoconazole, itraconazole, nefazodone, lopinavir, ritonavir) [see Warnings and Precautions (5.8), Drug Interactions (7.1)]."
}